Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Non-Current Deferred Tax Liability (2016 - 2018)

CytomX Therapeutics' Non-Current Deferred Tax Liability history spans 5 years, with the latest figure at $1.1 million for Q4 2018.

  • For Q4 2018, Non-Current Deferred Tax Liability changed N/A year-over-year to $1.1 million; the TTM value through Dec 2018 reached $1.1 million, changed N/A, while the annual FY2018 figure was $1.1 million, N/A changed from the prior year.
  • Non-Current Deferred Tax Liability reached $1.1 million in Q4 2018 per CTMX's latest filing, up from $520000.0 in the prior quarter.
  • In the past five years, Non-Current Deferred Tax Liability ranged from a high of $1.1 million in Q4 2018 to a low of $499000.0 in Q4 2014.
  • Average Non-Current Deferred Tax Liability over 5 years is $570181.8, with a median of $513000.0 recorded in 2016.
  • The largest YoY upside for Non-Current Deferred Tax Liability was 5.07% in 2017 against a maximum downside of 0.78% in 2017.
  • A 5-year view of Non-Current Deferred Tax Liability shows it stood at $499000.0 in 2014, then rose by 1.6% to $507000.0 in 2015, then increased by 1.18% to $513000.0 in 2016, then grew by 1.36% to $520000.0 in 2017, then skyrocketed by 118.65% to $1.1 million in 2018.
  • Per Business Quant, the three most recent readings for CTMX's Non-Current Deferred Tax Liability are $1.1 million (Q4 2018), $520000.0 (Q3 2017), and $539000.0 (Q2 2017).